BRISBANE, Calif., March 15 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that it has filed a Form 12b-25 with the Securities and Exchange Commission to request an extension to file its Annual Report on Form 10-K for the year ended December 31, 2006.
The additional time is required to allow InterMune to complete its review of certain additional disclosures and financial implications regarding the Company’s decision, previously announced on March 5, 2007, to discontinue its Phase 3 INSPIRE trial of Actimmune(R) (interferon gamma-1b) for the potential treatment of patients with idiopathic pulmonary fibrosis (IPF).
InterMune intends to file its Annual Report on Form 10-K as soon as it is able and within the 15-day extension period ending March 30, 2007.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary and fibrotic disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 in Phase 1a, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
Forward-Looking Statements
Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to the anticipated timing of InterMune’s filing with the SEC of its Annual Report on Form 10-K for the year ended December 31, 2006; and statements related to the progress, future patient enrollment in and timing of InterMune’s clinical trials and announcements of results thereof. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune’s actual results could differ materially from those described in InterMune’s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading ‘Risk Factors’ in InterMune’s annual report on Form 10-K filed with the SEC on March 13, 2006 (the “Form 10-K”) and updates included in the most recent Form 10-Q filed with the SEC on November 7, 2006 (the “Form 10-Q”), and other periodic reports filed with the SEC, including the following: (i) risks related to the development of our product and product candidates; (ii) risks related to timely patient enrollment and retention in clinical trials, including the use of third parties to conduct such clinical trials; (iii) risks related to achieving positive clinical trial results; (iv) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune’s other periodic reports filed with the SEC.
NOTE: Actimmune(R) is a registered trademark of InterMune, Inc.
InterMune, Inc.
CONTACT: Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com
Web site: http://www.intermune.com//
